FRSW107

DRUG5 trials

Sponsors

Kaifeng Pharmaceutical (Group) Co., Ltd., Jiangsu Gensciences lnc., Hangzhou Gensciences Biopharmaceutical Co., Ltd.

Conditions

Hemophilia ASevere Hemophilia A

Phase 1

A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII ，Fc Fusion Protein for Injection

CompletedNCT05251090

Jiangsu Gensciences lnc.Hemophilia A

Start: 2021-06-16End: 2022-05-09Updated: 2023-08-22

Phase 3

Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A

Not yet recruitingNCT06136507

Jiangsu Gensciences lnc.Severe Hemophilia A

Start: 2026-12-25End: 2026-12-31Target: 76Updated: 2024-06-20

Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment

Active, not recruitingNCT07663903

Hangzhou Gensciences Biopharmaceutical Co., Ltd.Severe Hemophilia A

Start: 2026-04-14End: 2027-06-01Target: 60Updated: 2026-09-08

Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.

Active, not recruitingNCT07684898

Hangzhou Gensciences Biopharmaceutical Co., Ltd.Severe Hemophilia A

Start: 2026-06-12End: 2027-06-21Target: 60Updated: 2026-09-04

Unknown Phase

A Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

Kaifeng Pharmaceutical (Group) Co., Ltd.Hemophilia A

Start: 2019-03-08End: 2020-05-31Target: 12Updated: 2020-05-08

Related Papers

Extended Half-Life of the Double-Chain Recombinant Factor VIII-Fc Fusion Protein (FRSW107) in Hemophilia a Patients

Blood2019-11-131 citations